Literature DB >> 2278969

Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11).

M Thangavelu1, O Olopade, E Beckman, J W Vardiman, R A Larson, T W McKeithan, M M Le Beau, J D Rowley.   

Abstract

Six patients with an aggressive leukemia/lymphoma disorder had a t(14;18) as well as either a t(8;14) (three patients) or a t(8;22) (three patients). Leukemia cells from all three patients with the t(8;22) had a mature B cell phenotype (Smlg + and TdT-), whereas two of three patients with the t(8;14) had a pre-B phenotype and were Smlg-. None of the patients with the t(8;22) had a prior history of follicular lymphoma, whereas two of the three patients with the t(8;14) had had a follicular lymphoma. The clinical, cytogenetic, and morphologic characteristics of these six patients along with eight previously reported cases with both the t(14;18) and the t(8;14), the t(8;22) or the t(2;8) are discussed.

Entities:  

Mesh:

Year:  1990        PMID: 2278969     DOI: 10.1002/gcc.2870020211

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  Acute lymphoblastic leukaemia of the L3 subtype in adults in the Northern health region of England 1983-99.

Authors:  M R Velangi; M M Reid; N Bown; G H Jackson; G P Summerfield; S J Proctor; P R A Taylor
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

2.  A 33-year-old man with an unclassifiable acute lymphoblastic leukemia.

Authors:  M H Kramer; J C Kluin-Nelemans; G C Beverstock; P M Kluin; R Bieger
Journal:  Ann Hematol       Date:  1991-05       Impact factor: 3.673

3.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 4.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

5.  Simultaneous occurrence of t(14;18) and t(8;22) common acute lymphoblastic leukemia.

Authors:  C Marosi; P Bettelheim; A Chott; U Köller; G Kreiner; G Steger; U Jäger; H Pirc-Danoewinata; K Lechner
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

6.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.

Authors:  Masao Nakagawa; Shinobu Tsuzuki; Keiichiro Honma; Osamu Taguchi; Masao Seto
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

8.  Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma.

Authors:  Robert P Hasserjian; German Ott; Kojo S J Elenitoba-Johnson; Olga Balague-Ponz; Daphne de Jong; Laurence de Leval
Journal:  J Hematop       Date:  2009-06-27       Impact factor: 0.196

9.  Translocation (14; 18) and (8; 22) in three patients with acute leukemia/lymphoma following centrocytic/centroblastic non-Hodgkin's lymphoma.

Authors:  W Fiedler; H J Weh; W Zeller; C Fonatsch; J Hillion; C Larsen; B Wörmann; D K Hossfeld
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

10.  Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.

Authors:  Naoto Tomita; Mami Tokunaka; Naoya Nakamura; Kengo Takeuchi; Junki Koike; Shigeki Motomura; Ko Miyamoto; Ako Kikuchi; Rie Hyo; Yoshihiro Yakushijin; Yasufumi Masaki; Soichiro Fujii; Takamasa Hayashi; Yoshiaki Ishigatsubo; Ikuo Miura
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.